Ductal adenocarcinoma of the pancreas: analysis of primary diagnosis and immunohistochemical features of the tumor
Keywords:
ductal adenocarcinoma, pancreas, desmoplastic stroma, immunohistochemistry, alpha-SMA, vimentin, desmin, fibronectin, CK7, CK18Abstract
Background: Today, pancreatic cancer (PC) ranks 11th worldwide among other cancers. Ranks 5th in terms of mortality. The incidence rate is increasing every year. The reason for the high mortality rate is late diagnosis of pancreatic cancer. Objective: analysis of primary diagnosis and determination of characteristic microscopic and immunohistochemical features of pancreatic ductal adenocarcinoma. Methods: the analysis of statistical data on the cancer registry of Ukraine 2015-2019rr and a comprehensive pathohistological and immunohistochemical study of 45 cases (surgical material of patients with ductal adenocarcinoma of the pancreas). Results: According to the Ukrainian Cancer Register in Ukraine, pancreas cancer (PCa) is diagnosed at stages II and III, in Zaporozhye and in the Zaporozhye region, PCa is diagnosed at stage IV of tumor development. Microscopic examination revealed that PDAC consists of a cancerous glandular-ductal compartment and a significant volume of stromal compartment, which makes up 67.61 84.24% of the total tumor area. Immunohistochemical study (IHC) using primary antibodies against α-SMA, vimentin, CK7, CK18, desmin, fibronectin. According to the results of the IHC study, it was found that the cytoplasmic expression of CK7 (M = 13.03% (Q1 = 8.40%; Q3 = 19.52%)) and CK18 (M = 8.54%) is determined in the cancer epithelium of ductulo-like and glandular-like structures. (Q1 = 5.99%; Q3 = 10.23%)). In the stromal compartment in fibroblasts and fusiform cells, the expression of vimentin is determined (M = 16.49% (Q1 = 10.64%, Q3 = 23.82%)), and around the ductulo-glandular cancer structures in pancreatic stellate cells, the expression of α- SMA (17.55% (Q1 = 11.43%, Q3 = 22.13%)). Significant expression of fibronectin and less expressive expression of desmin (M = 76.10% (Q1 = 70.23%; Q3 = 82.02%) and M = 24.01% (Q1 = 21.11 %; Q3 = 27.31%)). Conclusions: CK-7 is the optimal marker for the determination of the cancerous glandular ductal compartment of the PDAC. A well-developed fibroplastic stroma plays a significant role in the aggressive course of PDAC.
References
- Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors./ Prashanth Raw-la, Tagore Sunkara, Vinaya Gaduputi World J On-col. 2019. Vol 10(1). P.10-27- PMCID: PMC6396775 PMID: 30834048 doi: 10.14740/wjon1166
- Tumors of the pancreas Gill A.J., Klimstra D.S., Lam A.K., Washington M.R. In: WHO Classi-fication of Tumours 5th Edition. Vol. 1: Digestive System Tumours. Editorial Board, 2019. P. 295-372. ISBN 978-92-832-4499-8
- Addressing the challenges of pancreatic can-cer: future directions for improving outcomes. Hi-dalgo M., Cascinu S., Kleeff J., Labianca R., Löhr J.M., Neoptolemos J., Real F.X., Van Laethem J.L., Heinemann V. Pancreatology. 2015. Vol.15(1)/ P.8-18. DOI: 10.1016/j.pan.2014.10.001
- Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. M.Chiaravalli, M. Reni E. M. O'Reilly Cancer Treat Rev. 2017.Vol.60. P.32-43. doi: 10.1016/j.ctrv.2017.08.007.
- Morphological Changes in the Cells of the Ductal Adenocarcinoma of the Pancreas at Epitheli-al-Mesenchymal Transition T. N. Sotnikova1, G. R. Setdikova, O. V. Paklina, V. P. Shubin, M. V. Mnikhovich, A. S. Tsukanov, A. A. Karpov, M. M. Tavobilov, S. S. Lebedev, D. S. Ozerova. Journal of anatomy and histopathology. 2019; 8(3): 59-65. DOI: 10.18499/2225-7357-2019-8-3-59-65
- Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease James H. Monkman, Erik W. Thompson and Shivashankar H. Nagaraj Cancer 2019. Vol. 11(11) P.1745-1757 doi:10.3390/cancers11111745]
- Epithelial-Mesenchymal Transition in Pan-creatic Cancer: A Review Shuai W.,Shuai H., and Yu L.S. Biomed Res Int. 2017. Vol.5.– Р.1-10 doi: 10.1155/2017/2646148
- Pathology of pancreatic cancer Lena Haeberle, Irene Esposito Translational Gastroenter-ology and Hepatology 2019 Vol. 4(50) P.1-12 doi: 10.21037 tgh.2019.06.02
- Desmoplasia in pancreatic ductal adenocar-cinoma: insight into pathological function and therapeutic potential Andrew Cannon, Christopher Thompson, Bradley R Hall, Maneesh Jain, Sushil Kumar, Surinder K Batra Genes Cancer. 2018 Mar;9(3-4):78-86. doi: 10.18632/genesandcancer.171
- Bulletin of the National Cancer Registry No. 21 "Cancer in Ukraine, 2018-2019"
- Bulletin of the National Cancer Registry № 17 "Cancer in Ukraine, 2014-2015"
- Bulletin of the National Cancer Registry № 18 "Cancer in Ukraine, 2015-2016"
- Bulletin of the National Cancer Registry № 19 "Cancer in Ukraine, 2016-2017"
- Bulletin of the National Cancer Registry № 20 "Cancer in Ukraine, 2017-2018"
- Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions Histopathology, Cytopathology, and Molecular Pathology Bing Ren, Xiaoying Liu, and Arief A. Suriawinata The American Journal of PATHOLOGY Discoveries in Dasic and Transla-tional Pathobiology 2019 Jan;189(1):9-21. https://doi.org/10.1016/j.ajpath.2018.10.004
- Muin Sami Ahmad Tuffaha, Sergey Gichka, Hans Lother Guido Guski, Immunohistochemical diagnosis of tumors.Kyev, 2013. 224p.
- Cancer stem cells and mesenchymal stem cells in pancreatic ductal adenocarcinoma V. O. Tumanskyi, I. S. Kovalenko Pathologia. Volume 16. No. 1, January April 2019, 131-138р. DOI: 10.14739/2310-1237.2019.1.166476
- The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease C. McDonald-Hyman et al. The Journal of Clinical Investigation. 2018. Vol. 128. Issue 10. P. 4604- 4621. https://doi.org/10.1172/JCI95713
- Vimentin Diversity in Health and Disease F. Danielsson et al. Cells. 2018. Vol. 7. Issue 10. P. 147. https://doi.org/10.3390/cells7100147
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world.
The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.
